Nuwellis Inc vs Invesco S&P 500 High Div Low Volatility ETF — how do they compare? Nuwellis Inc trades at $1.5 (market cap $522.76K), while Invesco S&P 500 High Div Low Volatility ETF trades at $52.5. The key difference: Invesco S&P 500 High Div Low Volatility ETF is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| NUWE | SPHD | |
|---|---|---|
Market Cap | $522.76K | — |
Sector | Technology | — |
52-Week High | $220.50 | $53.55 |
52-Week Low | $1.42 | $46.96 |
Enterprise Value | -$1.29M | — |
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $1.49, down 8.59% over the past day, with a bearish technical outlook. The company reported a net loss of $17.52M in 2025, with a negative net income margin of -217.22%, though it has shown revenue growth and recent strategic expansions in pediatric care. A recent 35:1 reverse stock split was executed on June 26, 2026.
The outlook remains high-risk due to persistent losses and cash burn, but growth initiatives and new product development offer potential. Key risks include execution challenges and dependence on financing. Analyst sentiment is mixed, with a 50% buy and 50% hold rating among covered analysts.
SPHD trades at $52.6, up 0.63% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF focuses on high-dividend, low-volatility S&P 500 stocks, offering monthly income with a yield around 4.4%. Recent news highlights investor interest in dividend strategies amid market volatility, with articles from Zacks and ETF Trends in August 2026 emphasizing its stability and value appeal.
The outlook for SPHD is positive due to its defensive income strategy in uncertain markets, but risks include interest rate sensitivity and sector concentration. It suits investors seeking steady dividends with lower volatility, though growth may lag during bullish phases.
Trailing returns across standard periods
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.
Read more on SPHD →